Related Experiment Video
Updated: Jun 18, 2026
11:47
Treating SCA1 Mice with Water-Soluble Compounds to Non-Specifically Boost Mitochondrial Function
Published on: January 22, 2017
Coenzyme Q10 effects in neurodegenerative disease
Meredith Spindler1, M Flint Beal, Claire Henchcliffe
1Department of Neurology, Weill Medical, College of Cornell University, 525 east 68th Street, Suite F610, New York, NY, USA. mes9051@nyp.org
Neuropsychiatric Disease and Treatment
|December 8, 2009
Summary
Coenzyme Q10 (CoQ10) shows potential neuroprotective effects for neurodegenerative diseases. Clinical trials have yielded mixed results, necessitating further large-scale studies to confirm its therapeutic efficacy.
Area of Science:
- Biochemistry
- Neuroscience
- Mitochondrial Medicine
Background:
- Coenzyme Q10 (CoQ10) is vital for mitochondrial energy production.
- Mitochondrial dysfunction is implicated in various neurodegenerative disorders.
- Oxidative stress markers are elevated in neurodegenerative conditions.
Purpose of the Study:
- To review the potential of Coenzyme Q10 (CoQ10) as a therapeutic agent for neurodegenerative diseases.
- To evaluate the existing clinical evidence for CoQ10 in conditions like Parkinson's, Huntington's, and Alzheimer's disease.
Main Methods:
- Review of in vitro and animal models demonstrating CoQ10's neuroprotective properties.
- Analysis of clinical trial data from studies involving Parkinson's, Huntington's, Alzheimer's, Friedreich's ataxia, and ALS.
- Assessment of CoQ10's safety and tolerability profile.
Main Results:
- Preclinical studies suggest CoQ10 possesses neuroprotective capabilities.
- Clinical trials in various neurodegenerative diseases have produced equivocal or inconclusive findings.
- CoQ10 is generally well-tolerated with a favorable safety profile.
Conclusions:
- Coenzyme Q10 (CoQ10) is a promising candidate for neurodegenerative disease treatment due to its safety and preclinical data.
- Current clinical evidence is inconsistent, highlighting the need for high-dose, large-scale Phase III trials.
- Further research is required to definitively establish CoQ10's efficacy in managing neurodegenerative conditions.
Related Concept Videos
01:22Alzheimer's Disease: Treatment
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
01:27Pharmacodynamics in Geriatric Patients: Effects of Age
Age-related pharmacokinetic changes are extensively documented, but understanding age-related pharmacodynamic alterations is relatively limited. This knowledge gap can be partly attributed to the complexity of developing appropriate measures of drug responses compared to bioanalytical methods for determining drug concentrations.Most information regarding age-related differences in human pharmacodynamics originates from cross-sectional studies. However, these studies assume that observed mean...
01:26Alzheimer's Disease: Overview
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
01:23Alzheimer Disease ll: Pathophysiology
Alzheimer disease involves structural changes in the brain that begin long before symptoms appear. The most distinctive features are extracellular neuritic plaques and intracellular neurofibrillary tangles.Neuritic plaques form in the cerebral cortex and around blood vessels. These plaques contain a dense core of beta-amyloid (Aβ)—a toxic protein fragment that clumps outside neurons. The core is surrounded by damaged neuronal extensions, as well as reactive astrocytes and microglia. Abnormal...
01:24Parkinson's Disease: Treatment
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of its...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of its...
01:24Parkinson Disease ll: Pathophysiology
Parkinson disease (PD) is a progressive neurodegenerative disorder primarily affecting movement, with additional non-motor features. Its pathophysiology involves complex interactions among genetic susceptibility, environmental exposures, and cellular dysfunction, including dopaminergic neuron loss, protein aggregation, and mitochondrial impairment.Selective NeurodegenerationA key feature is the degeneration of dopaminergic neurons in the substantia nigra pars compacta, leading to reduced...